CAR-T Therapy: Defective Currently but Promising in the Future
DOI:
https://doi.org/10.54097/88tj2723Keywords:
chimeric antigen receptor, cancer immunotherapy, cytokine release syndrome, Immune effector cell-Associated Neurotoxicity SyndromeAbstract
Since CAR-T therapy was approved by the FDA in 2017, this therapy has become one of the most important cancer treatments for patients with some certain hematological malignancies. However, severe adverse effects, such as cytokine release syndrome (CRS) and neurotoxicity, cause low survival. The existed and approved drugs against these side effects would possibly become the trigger of other side effects or reduce the effect of therapy. Besides, CAR-T therapy that has been successfully applied in hematological malignancies shows weak efficacy in solid tumors. In this article, we introduce main limits of this promising therapy, integrate existed solutions and explore possible strategies to overcome these challenges. With more profound studies about CAR-T cell and associated side effects and limitations, we believe that there would be more novel strategies to optimize this revolutionary therapy will appear and be realized in the foreseeable future.
Downloads
References
Mitra A, Barua A, Huang L, et al. From bench to bedside: the history and progress of CAR T cell therapy. Frontiers in Immunology, 2023, 14: 1188049.
Sterner R C, Sterner R M. CAR-T Cell therapy: Current Limitations and Potential Strategies. Blood Cancer Journal, 2021, 11(4): 1–11.
Montironi C, Muñoz-Pinedo C, Eldering E. Hematopoietic versus Solid Cancers and T Cell Dysfunction: Looking for Similarities and Distinctions. Cancers, 2021, 13(2): 284.
Messmer A S, Que Y-A, Schankin C, et al. CAR T-cell therapy and critical care: A survival guide for medical emergency teams. Wiener Klinische Wochenschrift, 2021, 133(23-24): 1318–1325.
Neelapu S S, Locke F L, Bartlett N L, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. New England Journal of Medicine, 2017, 377(26): 2531–2544.
Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. Journal for ImmunoTherapy of Cancer, 2018, 6(1): 56.
Locke F L, Ghobadi A, Jacobson C A, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. The Lancet Oncology, 2019, 20(1): 31–42.
Sheth V S, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transplantation, 2021, 56(3): 552–566.
Qi X, Li J, Luo P. Glycyrrhizin for treatment of CRS caused by CAR T-cell therapy: A pharmacological perspective. Frontiers in Pharmacology, 2023, 14: 1134174.
Liu S, Deng B, Yin Z, et al. Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer Journal, 2020, 10(2): 15.
Davila M L, Riviere I, Wang X, et al. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. Science Translational Medicine, 2014, 6(224): 224ra25–224ra25.
Galván-Román J M, Rodríguez-García S C, Roy-Vallejo E, et al. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study. Journal of Allergy and Clinical Immunology, 2021, 147(1): 72-80.
Morris E C, Neelapu S S, Giavridis T, et al. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nature Reviews Immunology, 2021, 22: 85-96.
Ying Z, Huang X F, Xiang X, et al. A safe and potent anti-CD19 CAR T cell therapy. Nature Medicine, 2019, 25(6): 947–953.
Rafiq S, Hackett C S, Brentjens R J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nature Reviews. Clinical Oncology, 2020, 17(3): 147–167.
Sommermeyer D, Hill T, Shamah S M, et al. Fully human CD19-specific chimeric antigen receptors for T-cell therapy. Leukemia, 2017, 31(10): 2191–2199.
Kankeu Fonkoua L A, Sirpilla O, Sakemura R, et al. CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities. Molecular Therapy - Oncolytics, 2022, 25: 69–77.
Valkenburg K C, de Groot A E, Pienta K J. Targeting the tumour stroma to improve cancer therapy. Nature Reviews Clinical Oncology, 2018, 15(6): 366–381.
Sterner R M, Sakemura R, Cox M J, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood, 2019, 133(7): 697–709.
Bengsch B, Johnson A L, Kurachi M, et al. Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8 + T Cell Exhaustion. Immunity, 2016, 45(2): 358–373.
Adusumilli P S, Cherkassky L, Villena-Vargas J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Science Translational Medicine, 2014, 6(261): 261ra151–261ra151.
Lin J, Cao L, Zhu Y-J, et al. Enhance anti-lung tumor efficacy of chimeric antigen receptor-T cells by ectopic expression of C–C motif chemokine receptor 6. Science Bulletin, 2021, 66(8): 803–812.
Chinnasamy D, Yu Z, Theoret M R, et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. Journal of Clinical Investigation, 2010, 120(11): 3953–3968.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
